SCHEMBL2412752

SCHEMBL2412752

CCOCc1ccc(C(=O)OC)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL2 Q9Y4K0 1/20 0.59
MAPT P10636 6/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
NPC1 O15118 4/20 0.58
RAB9A P51151 4/20 0.58
MEN1 O00255 1/20 0.58
KMT2A Q03164 1/20 0.58
CA1 P00915 3/20 0.57
CA2 P00918 3/20 0.57
CA12 O43570 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57
CA14 Q9ULX7 1/20 0.57
ALDH1A1 P00352 2/20 0.55
KDM4E B2RXH2 1/20 0.55
GAA P10253 1/20 0.55
HPGD P15428 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7315382 0.95 LOXL2 (0.54) LOXL2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL6665979 0.90 LOXL2 (0.66) LOXL2MAPTSMN1; SMN2NPC1RAB9A
Ether SCHEMBL22720575 0.86 CA1 (0.61) LOXL2MAPTRAB9AMEN1KMT2A
SCHEMBL7218133 0.86 LOXL2 (0.56) LOXL2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL14281812 0.85 CA12 (0.67) MAPTSMN1; SMN2NPC1RAB9AMEN1
SCHEMBL9233919 0.84 TSHR (0.62) LOXL2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL12295745 0.84 LOXL2 (0.58) LOXL2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL10814960 0.84 LOXL2 (0.58) LOXL2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL9262378 0.83 NPC1 (0.56) LOXL2MAPTSMN1; SMN2NPC1RAB9A
SCHEMBL2607023 0.82 LOXL2 (0.66) LOXL2MAPTSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104418822-A Compound with xanthine oxidase inhibition activity, and use thereof NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD 2015-03-18 CN disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
CN-101068797-A Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof MITSUBISHI PHARMA CORP (JP) 2007-11-07 CN disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG LOXL2 3228/4885MAPT 3435/4885SMN1; SMN2 4773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.